Refinement of screening for familial pancreatic cancer
Open accessAbstract
Objective: Surveillance programmes are recommended for individuals at risk (IAR) of familial pancreatic cancer (FPC) to detect early pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC). However, the age to begin screening and the optimal screening protocol remain to be determined. Methods: IAR from non- CDKN2A FPC families underwent annual screening by MRI with endoscopic ultrasonography (EUS) in board-approved prospective screening programmes at three tertiary referral centres. The diagnostic yield according to age and different screening protocols was analysed. Results: 253 IAR with a median age of 48 (25–81) years underwent screening with a median of 3 (1–11) screening visits during a median follow-up of 28 (1–152) months. 134 (53%) IAR revealed pancreatic lesions on imaging, mostly cystic (94%), on baseline or follow-up screening. Lesions were significantly more often identified in IAR above the age of 45 years (p<0.0001). In 21 IAR who underwent surgery, no significant lesions (PDAC, pancreatic intraepithelial neoplasia (PanIN) 3 lesions, high-grade intraductal papillary mucinous neoplasia (IPMN)) were detected before the age of 50 years. Potentially relevant lesions (multifocal PanIN2 lesions, low/moderate-grade branch-duct IPMNs) occurred also significantly more often after the age of 50 years (13 vs 2, p<0.0004). The diagnostic yield of potentially relevant lesions was not different between screening protocols using annual MRI with EUS (n=98) or annual MRI with EUS every 3rd year (n=198) and between IAR screened at intervals of 12 months (n=180) or IAR that decided to be screened at ≥24 months intervals (n=30). Conclusions: It appears safe to start screening for PDAC in IAR of non- CDKN2a FPC families at the age of 50 years. MRI-based screening supplemented by EUS at baseline and every 3rd year or when changes in MRI occur appears to be efficient.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The 3-year survival of the former was 85%, as compared with that for HRI who developed symptomatic unresectable PDAC outside surveillance (25%).
“Importantly, the 3-year survival of the former was 85%, as compared with that for HRI who developed symptomatic unresectable PDAC outside surveillance (25%).”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [76]
Most (90%) resected screen-detected PDACs were found to be resectable, at an earlier stage than symptomatic PDAC.
“with most (90%) resected screen-detected PDACs found to be resectable, at an earlier stage than symptomatic PDAC.76”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [76]
Cites
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502 · see citing works
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784 · see citing works
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals
Canto, M. I., Hruban, R. H., Fishman, E. K., Kamel, I. R., Schulick, R., Zhang, Z., Topazian, M., Takahashi, N., Fletcher, J., Petersen, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.005 · Cited by 648 · see citing works
PALB2 mutations in European familial pancreatic cancer families
Slater, E., Langer, P., Niemczyk, E., Strauch, K., Butler, J., Habbe, N., Neoptolemos, J., Greenhalf, W., & Bartsch, D. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01425.x · Cited by 278 · see citing works
Vasen, H. F. A., Wasser, M., van Mil, A., Tollenaar, R. A., Konstantinovski, M., Gruis, N. A., Bergman, W., Hes, F. J., Hommes, D. W., Offerhaus, G. J. A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.048 · Cited by 152 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
European evidence-based guidelines on pancreatic cystic neoplasms
The European Study Group on Cystic Tumours of the Pancreas (2018) · Gut · doi:10.1136/gutjnl-2018-316027 · Cited by 1,417 · see citing works
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082 · see citing works
Goggins, M., Overbeek, K. A., Brand, R., Syngal, S., Del Chiaro, M., Bartsch, D. K., Bassi, C., Carrato, A., Farrell, J., Fishman, E. K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319352 · Cited by 659 · see citing works
Self-citationBoursi, B., Finkelman, B., Giantonio, B. J., Haynes, K., Rustgi, A. K., Rhim, A. D., Mamtani, R., & Yang, Y.-X. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.046 · Cited by 202 · see citing works
Long-term yield of pancreatic cancer surveillance in high-risk individuals
Overbeek, K. A., Levink, I. J. M., Koopmann, B. D. M., Harinck, F., Konings, I. C. A. W., Ausems, M. G. E. M., Wagner, A., Fockens, P., van Eijck, C. H., Groot Koerkamp, B., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-323611 · Cited by 164 · see citing works
Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review
Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158 · see citing works
Henrikson, N. B., Aiello Bowles, E. J., Blasi, P. R., Morrison, C. C., Nguyen, M., Pillarisetty, V. G., & Lin, J. S. (2019) · JAMA · doi:10.1001/jama.2019.6190 · Cited by 140 · see citing works
Sheel, A. R. G., Harrison, S., Sarantitis, I., Nicholson, J. A., Hanna, T., Grocock, C., Raraty, M., Ramesh, J., Farooq, A., Costello, E., et al. (2019) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0395-y · Cited by 36 · see citing works
Surveillance for neoplasia in the pancreas
Overbeek, K. A., Cahen, D. L., Canto, M. I., & Bruno, M. J. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.10.013 · Cited by 28 · see citing works
Stoffel, E. M., McKernin, S. E., & Khorana, A. A. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00629 · Cited by 22 · see citing works
- Authors
- Bartsch, D. K., Slater, E. P., Carrato, A., Ibrahim, I. S., Guillen-Ponce, C., Vasen, H. F. A., Matthäi, E., Earl, J., Jendryschek, F. S., Figiel, J., Steinkamp, M., Ramaswamy, A., Vázquez-Sequeiros, E., Muñoz-Beltran, M., Montans, J., Mocci, E., Bonsing, B. A., Wasser, M., Klöppel, G., Langer, P., Fendrich, V, & Gress, T. M.
- Affiliations
- Philipps University of Marburg (DE)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Leiden University Medical Center (NL)
- Department of Medical Oncology, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
- Department of Radiology, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
- Department of Pathology, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
- Technical University of Munich (DE)
- Corresponding author
- Bartsch, D K
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2016-05-24
- Volume
- 65
- Issue
- 8
- Pages
- 1314-1321
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2399178592
- Cited by
- 85
- References
- 5
- Citations by year
- 2024: 15 · 2023: 7 · 2022: 5 · 2021: 9 · 2020: 3 · 2019: 10 · 2018: 22 · 2017: 9 · 2016: 5
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Deutsche Krebshilfe (111092)
- Instituto de Salud Carlos III (PI09/02221, RD12/0036/0034)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- familial pancreatic cancer, pancreatic ductal adenocarcinoma, cancer screening, high-risk individuals, magnetic resonance imaging, endoscopic ultrasound, pancreatic cysts, pancreatic intraepithelial neoplasia, screening frequency, age at screening initiation, diagnostic yield
- MeSH terms
- Carcinoma, Female, Germany, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Staging, Pancreas, Pancreatic Neoplasms, Time Factors, Age of Onset, Endosonography, Early Detection of Cancer, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
